Dylann Cohn-Emery

The responses to epcoritamab plus rituximab/lenalidomide for patients with relapsed/refractory follicular lymphoma appear comparable between those with and without disease progression within 24 months of first-line chemotherapy in the phase 1/2 EPCORE NHL-2 trial.

Patients with hepatocellular carcinoma treated from 2018 to 2021 experienced better outcomes than patients treated in the preceding decade, according to a recent study.

A potential efficacy benefit has been observed with lintuzumab-Ac225 plus salvage therapy for patients with relapsed/refractory acute myeloid leukemia.

Patients with operable, locally advanced triple-negative breast cancer experienced notable improvements in survival following treatment with neoadjuvant carboplatin plus sequential taxane-anthracycline neoadjuvant chemotherapy.

Patients with mismatch repair deficient (dMMR) colon cancer experienced a high rate of major pathologic complete response following treatment with nivolumab and ipilimumab for 4 weeks.

Results from the phase 3 CANOPY-A trial failed to show improved disease-free survival with adjuvant canakinumab in completely resected non–small cell lung cancer.

The phase 1/2 KRYSTAL-1 trial showed the use of adagrasib for KRAS G12C mutant-non–small cell lung cancer yielded results of positive intracranial activity and central nervous system penetration.

At a minimum follow-up of 3 years, an improvement in overall survival was seen in patients with metastatic non–small cell lung cancer treated with nivolumab and ipilimumab in combination with chemotherapy.

Results of the ENZAMET trial presented at 2022 ASCO continue to support use of enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.

Results of the phase 2 AURELIO-03 trial show SOT101 plus PD-1 inhibition induced responses in patients with advanced solid tumors.

Patients with non-melanoma skin cancer achieved promising antitumor activity following treatment with RP1 and nivolumab.

Data presented at 2022 ASCO GU of front nivolumab plus cabozantinib for renal cell carcinoma show persistent overall survival benefit versus sunitinib.

Patients with advanced hepatocellular carcinoma achieved a statically significant and clinically meaningful survival benefit following treatment with pembrolizumab and best supportive care in the second line.

A non inferiority design was presented at ASH 2021 for acalabrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia or small lymphocytic leukemia.

A post-hoc analysis of a phase 3 trial presented at 2021 ASH indicate that acalabrutinib may be favorable in terms of toxic burden and cardiovascular-related events when compared against ibrutinib for treating chronic lymphocytic leukemia.

Research from the 2021 San Antonio Breast Cancer Symposium suggests pathologic complete response and event-free survival were not significantly impacted by race for women with high-risk breast cancer who underwent targeted neoadjuvant chemotherapy.

There remains a therapeutic challenge with understanding and treating patients with accelerated myeloproliferative neoplasms.

Patients with renal cell carcinoma experienced a better overall survival when treated with nivolumab plus cabozantinib regardless of whether or not they underwent a nephrectomy previously.

Francesco Passamonti, MD, discusses the future of treatment for patients with polycythemia vera such as adaptive therapies and the utilization of novel targets.

Pralsetinib was well tolerated, while demonstrating robust and durable anti-tumor activity when treating heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.

A phase 1 trial of the investigational agent CLN-081 indicates antitumor activity coupled with a tolerable safety profile as treatment of patients with non–small cell lung cancer and EGFR exon 20 insertion mutations.

Five-year follow-up data from the SOLO-1 trial continue to show progression-free survival benefit of olaparib as maintenance therapy following platinum-based chemotherapy in the frontline setting for ovarian cancer.

Patients with newly diagnosed ovarian cancer who had interval debulking surgery and visible residual disease showed promising outcomes when treated with the PARP inhibitor niraparib, according to a post hoc analysis of a phase 3 clinical trial.

Patients with advanced lung cancer whose tumors harbor an NTRK gene fusion with or without central nervous system metastases were found to have high response rates, durable responses, and extended survival benefit with larotrectinib.

As third- or fourth-line therapy for patients with metastatic RCC, tivozanib hydrochloride demonstrated a statistically significant increased quality-adjusted time without symptoms of disease and toxicity compared with sorafenib.

Lenvatinib monotherapy was an effective first-line therapy for patients with unresectable hepatocellular carcinoma, according to data from a retrospective, real-world analysis.

The study found that favorable outcomes after treatment with lapatinib (Tykerb) were demonstrated by early declines in circulating tumor cell counts (CTCs) in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs.

The ongoing phase 1/2 DREAMM-6 trial found that the addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.

A phase 1 trial found that MEDI-570 demonstrated clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.